Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.
In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2-14.7) compared with 9 months (95% CI, 4.2-13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24-0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.
Ranjan, Tulika; Sengupta, Soma; Glantz, Michael J.; Green, Richard M.; Yu, Alexander; Aregawi, Dawit; Chaudhary, Rekha; Chen, Ricky; Zuccarello, Mario; Lu-Emerson, Christine; Moulding, Hugh D.; Belman, Neil; Glass, Jon; Mammoser, Aaron; Anderson, Mark; Valluri, Jagan; Marko, Nicholas; Schroeder, Jason; Jubelirer, Steven; Chow, Frances; Claudio, Pier Paolo; Alberico, Anthony M.; Lirette, Seth T.; Denning, Krista L.; and Howard, Candace M., "Cancer Stem Cell Assay-Guided Chemotherapy Improves Survival of Patients With Recurrent Glioblastoma in a Randomized Trial" (2023). Department of Neurosurgery Faculty Papers. Paper 204.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.